Effects of BPA on Insulin and Glucose Responses
Effects of Oral Ingestion of BPA on Insulin and Glucose Responses
1 other identifier
interventional
11
1 country
1
Brief Summary
The National Institutes of Health has encouraged research examining effects of BPA, yet evidence in humans evaluating the effects of BPA on insulin and glucose concentrations remains exclusively associative in nature. Thus, the primary purpose of this study is to determine whether an acute oral ingestion of BPA impacts insulin and glucose concentrations, and other endocrine factors (Pro-insulin, C-Peptide, Estrogen, triglycerides). Findings from this pilot study will inform public health recommendations for food packaging and provide much needed experimental evidence as to whether BPA poses any public health risk.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2016
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2016
CompletedFirst Submitted
Initial submission to the registry
February 8, 2018
CompletedFirst Posted
Study publicly available on registry
February 26, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 14, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
February 14, 2019
CompletedFebruary 18, 2019
February 1, 2019
2.5 years
February 8, 2018
February 14, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Change From Baseline Glucose at 180 Minutes
Glucose concentrations will be assessed before and in response to a 75 gram Oral Glucose Tolerance Test
9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180
Secondary Outcomes (5)
Change From Baseline Insulin at 180 Minutes
9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180
Change From Baseline Estrogen at 180 Minutes
9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180
Change From Baseline C-Peptde at 180 Minutes
9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180
Change From Baseline Pro-Insulin at 180 Minutes
9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180
Change From Baseline Triglycerides at 180 Minutes
9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180
Study Arms (3)
Placebo
PLACEBO COMPARATORParticipants consume Vanilla Wafer cookie
BPA 4 ug/kg BW
EXPERIMENTALParticipants consume 4 ug/kg BW of BPA on a Vanilla Wafer Cookie
BPA 50 ug/kg BW
EXPERIMENTALParticipants consume 50 ug/kg BW of BPA on a Vanilla Wafer Cookie
Interventions
Eligibility Criteria
You may qualify if:
- BMI = 18.5-35
- Age 18-50 years
- Non-smoking
- English speaking
You may not qualify if:
- History of infertility
- Type 2 or Type 1 diabetes
- Cardiovascular disease, or any other metabolic disease/complication
- Hypertension (systolic blood pressure ≥140, diastolic blood pressure ≥90) assessed by sphygmomanometer
- History of major psychiatric illness, drug abuse, or unsafe dieting practices
- History of bariatric surgery
- Pregnant women or women expecting or trying to become pregnant
- Participating in other studies
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
California Polytechnic State University
San Luis Obispo, California, 93405, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Todd Hagobian, PhD
California Polytechnic State University-San Luis Obispo
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- Double-blinded study; Study statistician computer generated randomization
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
February 8, 2018
First Posted
February 26, 2018
Study Start
September 1, 2016
Primary Completion
February 14, 2019
Study Completion
February 14, 2019
Last Updated
February 18, 2019
Record last verified: 2019-02
Data Sharing
- IPD Sharing
- Will not share
No plan to share data in this pilot study